Renal cell carcinoma (RCC) is the most common type of kidney cancer1,2

Approximately 9 of 10 kidney cancers are RCC2
20% to 30% have advanced metastatic disease at INITIAL DIAGNOSIS1

VOTRIENT—A therapy designed to fight advanced or metastatic renal cell carcinoma at the source from the start3-5*

*The mechanism of action is based on in vivo and in vitro studies.

References: 1. Petejov N, Martinek A. Renal cell carcinoma: review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(2):183-194. 2. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004. 3. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018. 4. Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15(6):539-547. 5. Prager GW, Poettler M, Unseld M, Zielinski CC. Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res. 2012;1(1):14-25.